



Universiteit  
Leiden  
The Netherlands

## **Decision-making in severe traumatic brain injury: patient outcome, hospital costs, and research practice**

Dijck, J.T.J.M. van

### **Citation**

Dijck, J. T. J. M. van. (2021, September 16). *Decision-making in severe traumatic brain injury: patient outcome, hospital costs, and research practice*. Retrieved from <https://hdl.handle.net/1887/3210899>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3210899>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <https://hdl.handle.net/1887/3210899> holds various files of this Leiden University dissertation.

**Author:** Dijck, J.T.J.M. van

**Title:** Decision-making in severe traumatic brain injury: patient outcome, hospital costs, and research practice

**Issue Date:** 2021-09-16



# CHAPTER 12

## **GENERAL DISCUSSION AND FUTURE PERSPECTIVES**



Humans have suffered from the consequences of traumatic brain injuries (TBI) from the beginning of mankind and will continue to do so in the future. For ages, people have attempted to minimize the consequences of TBI by examining and treating affected individuals.<sup>1</sup> Extensive experience and improvements in medical treatments from the last century resulted in substantial progress in the survival and outcome of severe TBI (s-TBI) patients (Glasgow Coma Score (GCS) of 3–8).<sup>2-5</sup>

Patients with s-TBI (29%–40%)<sup>6,7</sup> and vs-TBI (GCS 3–5; 19.6%–23%)<sup>6,7</sup> are nowadays able to achieve so-called ‘favourable’ outcome.<sup>8,9</sup> Most s-TBI patients (40%–65%)<sup>6,7</sup> however still die or survive with long-term disabilities<sup>2,3,8-11</sup>, which also negatively affects the quality of life of most proxies.<sup>12-14</sup> Outcome is usually worse in patients with higher TBI severity (i.e. lower GCS, pupillary abnormalities), intracranial abnormalities on first CT scan, extracranial injuries and need for surgical intervention.<sup>3,6,7,15-17</sup> Despite all available patient outcome data, it remains challenging to interpret, generalize, value, and use this data for acute treatment decision-making.

Acute treatment decisions are poorly supported by high- or even moderate quality evidence and accurate prognostic algorithms, leaving ample room for uncertainty.<sup>18-23,47</sup> Also, available guidelines do not cover all relevant topics due to a lack of supporting evidence.<sup>18</sup> Non-adherence to guidelines and treatment variation seem understandable in light of such lack of certainty.<sup>24-27</sup> It even remains unclear how specific factors substantiate the acute treatment decision-making process.<sup>28-31</sup> As a result, the decision to initiate acute treatment or not in s-TBI patients or discontinue critical care in the subacute period poses major medical and ethical dilemmas to physicians.

This *general discussion* elaborates on the role of patient outcome and in-hospital costs in the acute treatment decision-making process in s-TBI patients.

## Main findings and interpretation

### Patient outcome

Providing healthcare is about doing ‘right’ for individual patients and about better health for populations.<sup>32</sup> Physicians have a responsibility to customize treatment strategies to achieve best possible patient outcome that is respectful of and responsive

to individual patient preferences, needs, and values.<sup>32</sup> Choosing an acute treatment strategy that is proportional and leads to best possible patient outcome is however difficult. This is mainly caused by uncertainties on future patient outcome, especially regarding outcome prediction and outcome valuation.

### Patient outcome prediction

Because providing healthcare is about patient outcome in the future, it is necessary to use a prediction of that outcome for acute treatment decisions. Knowing what specific outcome will be achieved after a specific treatment is likely to improve decision-making.<sup>30,31,33-35</sup>

Unfortunately, physicians appear to be unable to make accurate outcome predictions (Table 1).<sup>22,33,36,37</sup> Validated prognostic models, such as IMPACT and CRASH<sup>38,39</sup>, have been developed to assist physicians with TBI outcome prediction, but they have not been widely implemented in clinical care.<sup>40-44</sup> Although IMPACT and CRASH models display good discriminative ability in validation studies<sup>40,41</sup>, they are, like experienced physicians, considered to be too inaccurate on individual level predictions. Heterogeneity between individual patients with variable injuries, pathophysiology, and treatments makes prognostication difficult and uncertain. Another limitation of available prognostic models is that they only include robust short-term outcome measures like mortality and functional outcome. Although robustness is a good epidemiological attribute of clinical studies it misses personal human properties like long-term physical, cognitive, emotional and behavioural outcome, or satisfaction with life.<sup>33,38-45</sup> This is problematic, because these long-term consequences of s-TBI are highly relevant to include in outcome assessment.<sup>46</sup>

**Table 1.** Difficulties in outcome prediction in TBI patients (chapter 6)<sup>47</sup>

#	Difficulties in random order.
1	The heterogeneous nature of s-TBI and concurring comorbidities and their unknown effect on outcome.
2	Unclear/incomplete clinical information, including the patient's neurological state and level of consciousness.
3	Largely unknown pathophysiological mechanisms of brain injury and inherent degree of brain plasticity.
4	Prediction models do not include long-term (health-related) quality of life, although long-term changes have been reported and patients/proxies are known to value this outcome.
5	Prediction models are based on large retrospective data sets that do not necessarily reflect current or future treatment strategies.

High prognostic accuracy is indispensable when a prediction is used to substantiate individual acute treatment decisions. Relatively small mathematical inaccuracies

can have disastrous clinical consequences. It remains unknown how high this accuracy must be and what cut-offs should be used for decision-making. There are peer reviewed recommendations that consider it reasonable to pursue non-aggressive care in patients with a >85% chance of death or 'unfavourable' outcome.<sup>34</sup> If a physician would have followed this recommendation, a 28-year old patient with a CRASH-model predicted risk of death at 14 days of 91.8% and a risk of an 'unfavourable outcome' at 6 months of 95.7%, that achieved 'favourable' outcome and was able to live independently, would have probably died after treatment-limiting decisions.<sup>48</sup>

Despite many efforts to improve outcome prediction, there is substantial inaccuracy in today's prognostic abilities. Every effort must be made to prevent that patients are unfairly deprived of potentially beneficial care because of erroneous prognostication or poorly chosen cut-offs. It is therefore essential that inherent uncertainties of outcome prediction are acknowledged in the acute decision-making process. Only the best possible approximation of expected patient outcome should be used and opportunities to improve prognostic accuracy should be explored.

### **Patient outcome valuation**

Valuation of predicted patient outcome is about judging the favourability of a patients' future health status and about defining how 'acceptable' or 'unacceptable' that health status is to patients, proxies and societies. Its importance for acute treatment decision-making seems obvious. Common sense dictates that acute treatment should be initiated or continued when outcome is judged 'acceptable', and withheld or discontinued when outcome is judged 'unacceptable'.

A cut-off point for 'acceptability' of outcome would be useful, but an exact definition of 'acceptable' or 'unacceptable' outcome remains elusive, and is probably impossible to determine.<sup>49,50</sup> Any cut-off point will be highly arbitrary and can never account for the countless outcome possibilities and numerous variations in peoples' specific contexts, and ever-changing desires or interpretations of well-being or 'the good life'. Life can be judged worth sustaining because it has intrinsic value to relatives and friends, or because of cultural or religious reasons.<sup>51</sup> (*chapter 6*)

Several scales and checklists have been developed to quantify the individual and societal impact of TBI, and to improve the assessment of medical treatment efficacy.<sup>52</sup> Nonetheless, the most frequently used measures have important limitations in specifying the individual 'acceptability' of outcome. The reliability of



these measures for outcome valuation and their usefulness in the acute decision-making process of s-TBI patients remains disputed.

### *Patient mortality*

The most frequently used and most straightforward outcome measure. Death is usually considered to be the worst possible outcome that should be prevented at any cost.<sup>53</sup> However, in s-TBI patients, survival with severe post-traumatic deficits can be a fate worse than death.<sup>54-58</sup> When considering the possibility of very severe cognitive, emotional, and physical disabilities, life and death are not necessarily equal to 'acceptable' and 'unacceptable'. As such, acute treatment decisions should not solely be based on predicted mortality.

### *Functional outcome*

The Glasgow Outcome Scale (GOS) is the most highly cited outcome measure in brain injury studies.<sup>59-61</sup> Its use as TBI outcome measure is recommended by many organizations.<sup>60</sup> It assesses multiple aspects of life to determine the impact of TBI on patient functional outcome with a focus on social recovery. It uses dichotomous endpoints, in which 'favourable' outcome (the ability to function independently, see Table 2), is usually considered to be the 'acceptable' outcome. The introduction of the Glasgow Outcome Scale Extended (GOSE) and the structured interview<sup>61</sup> have solved points of criticism on validity and lack of sensitivity in the higher functional end of the scale, but there are remaining issues.<sup>52,60,61</sup>

The 'favourable'/'unfavourable' division remains arbitrary and ignores a patients' or proxy's perception of satisfaction with life. Patients with severe disability who are dependent in daily life (defined as 'unfavourable') can still judge their health status to be 'acceptable'.<sup>60</sup> But the other way around is also possible. Some studies classify 'upper severe disability' (GOS-E) to be 'favourable', while probably most physicians, researchers and healthy individuals would classify this outcome as 'unacceptable' within their own social and cultural context.<sup>50,62</sup>

Instead of using dichotomized outcome, sliding dichotomy or proportional odds methods are considered to be more informative. These methods are increasingly popular, but still have insufficient sensitivity to detect all changes. Subtle changes can be highly valuable for a patients' wellbeing, without having a measurable impact on pre-defined categories.<sup>60</sup>

The GOS/GOSE is a very useful functional outcome measure, but does not include the essential subtleties of well-being. The use of 'favourable' and 'unfavourable' as substitutes for 'acceptable' and 'unacceptable' outcome is inadequate. These terms should not be interpreted or used as such in acute treatment decision-making.

**Table 2** Explanation of Glasgow Outcome Scale (- Extended).<sup>61</sup>

Glasgow Outcome Scale (GOS)	Glasgow Outcome Scale – Extended (GOSE)	Brief description	
2. Death	2. Death	Death	Unfavourable
3. Vegetative state	3. Vegetative state	Absence of awareness of self and environment	
4. Severe disability	6. Lower severe disability 7. Upper severe disability	Needs full assistance in daily life Needs partial assistance in daily life	
9. Moderate disability	10. Lower moderate disability 11. Upper moderate disability	Independent, but cannot resume work/school or all previous social activities Some disability exists, but can partly resume work or previous activities	Favourable
8. Good recovery	12. Lower good recovery	Minor physical or mental deficit that affects daily life	
	13. Upper good recovery	Full recovery or minor symptoms that do not affect daily life	

### *Health-Related Quality of Life (HRQoL)*

HRQoL measures focus on a patient's view on the impact of TBI and a certain health status on their (quality of) life. They are a multi-dimensional concept including physical, mental, emotional, and social functioning. Generic HRQoL instruments are designed to investigate particular interventions or populations.<sup>63</sup> Disease-specific HRQoL measures have been specifically designed for a disease and are assumed to be more sensitive to that disease, allowing more precise outcome information.

The Quality of Life after Brain Injury (QOLIBRI) is an example of a TBI-specific HRQoL measure.<sup>64</sup> The applicability of the QOLIBRI in s-TBI patients however remains unclear. Most s-TBI patients suffer from cognitive impairment and communicative difficulties. Patients are hardly able to complete the questions, and, likely for this reasons, the QOLIBRI has only been validated in patients without substantial post-traumatic cognitive restraints.<sup>65</sup> Proxies are often unable to adequately substitute a patients view.<sup>52</sup> The QOLIBRI cut-off point of 60 (score 0 to 100) for quantifying a 'good' HRQoL also remains unclear and is prone for subjectivity.<sup>66</sup> Generic HRQoL instruments like the SF-36, EQ-5D, or WHOQOL-BREF are also considered to be less useful in patients with moderate or severe TBI (GCS 3-12).<sup>67,68</sup>

### *Individualized approach*

The alternative of simply asking individual s-TBI patients in the acute setting to value their predicted outcome could be helpful, but is impossible. Patients after s-TBI have an inability to participate in the decision-making process by definition and their preferences, needs, and values are therefore unknown.<sup>31</sup> Written advanced directives are rarely available and patients have rarely discussed preferences with proxies.<sup>49,51</sup> In addition, proxies, as surrogate decision-makers, are mostly unavailable, unprepared, confused by uncertainty and hope, and unequipped to fully understand the uncertainties of acute clinical decision-making. Proxies might even misjudge or misrepresent patients' preferences.<sup>69,70</sup>

As mentioned in *chapter 6*, even without mental incapacity due to s-TBI, individuals are generally unable to predict accurately what future quality of life would be 'acceptable' or 'unacceptable' to them. People often underestimate their ability to adapt to a level of disability they previously considered 'unacceptable'.<sup>33</sup> Survivors of s-TBI that had achieved a so-called 'unfavourable outcome' defined by the Glasgow Outcome Scale (Table 2) after a decompressive craniectomy, or their caregivers, appeared to have changed their perception of 'a good quality of life'. They were satisfied and would even have provided retrospective consent for the intervention.<sup>71,72</sup> This absence of a linear connection between disabilities and experienced quality of life is known as the disability paradox<sup>73</sup> and is also seen in patients suffering from locked-in syndrome or Duchenne.<sup>72,74-76</sup>

### *A physician's perspective*

Given the reservations regarding a patient's or proxies preferences, it is inevitable that a physician's outcome valuation is included in the acute treatment decision-making process. Although physicians have an important role in protecting a patient's interests, their valuation and subsequent acute treatment-decisions might not always honour a patients' preferences. Their valuations can be influenced by local policy, specialized medical training, personal and professional experiences, but also by individual values, religious beliefs, and cultural background. This might jeopardize the objective selection of an individualized healthcare strategy that aims to achieve 'acceptable' patient outcome.

An important risk in decision-making is a physicians' strong belief in high mortality and 'unfavourable' outcome rates, as it is likely to contribute to clinical nihilism and the overall belief that treatment is ineffective.<sup>47</sup> This focus on poor prognosis is not necessarily in line with reported patient outcome<sup>6,7</sup> but might lead to withholding, withdrawing, or decreasing intensity of potentially beneficial treatment(s). The

negative feedback makes other involved carers (i.e. nurses) pessimistic, which can result in limited care efforts, which in turn negatively influences patient outcome.<sup>77</sup>

Not realizing their own contribution, worse outcome will initially confirm their individual beliefs and later spread by the inclusion in clinical studies or when included in prognostic models.<sup>77</sup> As much as 63% of deaths in trials investigating s-TBI patients were registered after decisions to withdraw life-sustaining therapies.<sup>78</sup> Trial mortality rates could have been influenced by this large number of withdrawals, and could further contribute to maintain the belief in poor prognosis, resulting in more withdrawals of care and worse outcome.<sup>78</sup> Physicians need to be aware of this self-fulfilling prophecy and its potential effect on treatment decision-making.<sup>79</sup>

Some restraint in treatment-limiting decisions in the acute phase might be prudent given the uncertainties on patient outcome prediction and outcome valuation and the irreversible consequences of these decisions.

### **Can we fix the acute treatment decision-making process?**

Acute treatment decision-making in s-TBI patients is highly complex and many problems with uncertainty in outcome prediction and outcome valuation will be difficult to solve. Despite this complexity, physicians will continue to make treatment decisions at the best of their abilities. An improvement in the quality of these inevitable acute treatment decisions could be achieved by deliberately delaying early treatment-limiting decisions in s-TBI patients with substantial prognostic uncertainty. This may not only prevent premature treatment-limiting decisions, but also means that these patients will receive optimal acute treatment, which hopefully allows best possible recovery, probably at the cost of increasing neuro-critical care costs.

#### *The necessity for more time*

The proposed strategy provides more time to measure and collect early key critical care variables to improve prognostic ability and to reconstruct a patients' preferences, values, and treatment wishes.<sup>31,80-82</sup> This valuable information on clinical progress, neurological recovery, and a complete, objective and consistent evaluation of rapidly evolving imaging modalities (i.e. CT and MRI) only becomes available with extra time and will substantially improve diagnostics and prognostication.<sup>83-86</sup> More time also allows multidisciplinary counsel including moral deliberation on individual patient or proxy preferences. All this additional information is highly valuable, and indispensable for a decision-making process.<sup>31,87,88</sup>

Although delaying treatment-limiting decisions seems to be a viable solution to improve decision-making, it is not common practice. Treatment-limiting decisions are reported within 2 days after injury in up to 70% of s-TBI patients.<sup>78,89,90</sup> Although physicians have best intentions, these early decisions deprive patients of a chance for successful recovery and usually result in clinical deterioration and death.<sup>78,89</sup> Limiting treatment within 2 days after injury seems to be disproportional and morally unjustified given the uncertainties on future outcome.<sup>82</sup>

It remains unknown how much extra time is necessary to sufficiently improve prognostic accuracy to avoid the withholding of potentially beneficial treatments. The Neurocritical Care Society recommends to use a 72-hour observation period for devastating brain injury patients to determine clinical response and delay decisions regarding withdrawal of life-sustaining treatment.<sup>91</sup> Longer decision-making intervals of a week or even 10 days have also been recommended, awaiting adequate control of cerebral edema, injurious neuroinflammation, and associated intracranial hypertension.<sup>92,93</sup> Delaying any conclusions about prognosis to after 72 hours is also advised for brain injury after cardiac arrest.<sup>94</sup>

### *Treatment-limiting decisions*

There are advantages of the proposed strategy, but an unrestricted endeavour for sustaining life by providing optimal acute treatment to all s-TBI patients is undesirable and unrealistic for two main reasons:

First, providing acute treatment might be considered disproportional from a patients perspective. Treatment can be against patients' and proxies' preferences and values.<sup>78,89,95</sup> When achieved outcome becomes 'unacceptable', or when a combination of different features indicates very low chances of regaining an 'acceptable' outcome, or when treatment has become disproportionate given the outcome, treatment-limiting decisions should be considered. Treatment-limiting decisions can be inevitable and morally justified. Death is unwanted, but catastrophic conditions such as unresponsive wakefulness syndrome or minimally conscious state are accompanied by very severe disabilities and enormous challenges for both patients and proxies that should not be disregarded.<sup>96,97</sup> Many will doubt this is a human life worth living.<sup>98</sup> (*chapter 6*)

Several reasons to consider early treatment-limiting decisions are listed in textbox 1 (*chapter 6*).<sup>47</sup> This list is meant to serve as a starting point for further discussion, rather than constitute a final list of reasons. Although all focus group participants from *chapter*

6 were highly regarded experts in the field, clinical situations might not be similar to the Dutch situation and their expert opinion might not be shared. This could limit the generalizability and practicality of the list, but emphasises that continued discussions and research on treatment-limiting decisions are essential.

**Textbox 1: Reasons, including potential outcome perspectives, to strongly consider treatment-limiting decisions (chapter 6) <sup>47</sup>**

1. Brain death, from a patient's perspective (not considering interests regarding organ donation procedures). <sup>99,100</sup>
2. (chronic) Unresponsive wakefulness syndrome. <sup>96,101</sup>
3. Minimally conscious state – (minus) (i.e. visual pursuit, localization of noxious stimuli, appropriate smiling or crying to emotional stimuli). <sup>101,102</sup>
4. An available, unquestionable, written and signed specific advance directive of the patient that prohibits treatment in a specific situation (possibly related to expected outcome).
5. A proxy opinion that is unquestionably based on patient preferences and that is not in conflict with the attending medical teams' considerations, that prohibits treatment in a specific situation (possibly related to expected outcome).
6. A patient's view (or when necessary a reconstructed vision through surrogated) on life and quality of life is contrary to the outcome that can be expected from the best available prognostic models.
7. From a societal perspective, treatment costs along the whole chain of care that are not cost-effective and higher than the maximum amount that has been decided by national legislation.

*The societal perspective*

Second, treatment can be considered disproportional from a societal perspective. Healthcare is not only about individuals but also about improving health of populations. <sup>12-14,32</sup> The proposed strategy of providing acute treatment to more s-TBI patients is likely to substantially increase in-hospital costs. On a large scale, this might affect restricted healthcare budgets and jeopardize vulnerable healthcare systems or societal health. <sup>3,103</sup> This is undesirable in a time where politicians are already struggling to restrict the increasing worldwide economic burden of healthcare. <sup>103</sup> Despite governmental restrictions, The Netherlands, with 17.3 million inhabitants

in 2019, spent as much as €80.9 billion on healthcare in 2019, an increase of 4.8% compared to 2018.<sup>104</sup> This accounts for 10% of total gross domestic product<sup>104</sup>, similar to many other high-income countries: 11.5% (9.6% – 12.4).<sup>103</sup> Although treating more s-TBI patients could be legitimized by more patients with improved and hopefully ‘acceptable’ outcome, the future of healthcare systems requires prudence and optimal use of restricted resources.

Justice, as one of four moral principles in medical ethics (Table 3), requires the fair distribution of benefits, risks and limited medical goods and services.<sup>105-107</sup> With respect to its many variations, this is in line with the principle of utilitarianism, which seeks to maximize the well-being of most of the people, instead of the individual.<sup>108,109</sup> Incorporating these principles in acute treatment decision-making could mean that resources, potentially beneficent for an individual patient, are ethically restricted for the wellbeing of the entire society. In line with this, resources should not be used on so-called ineffective and disproportional treatments in s-TBI patients with a very low chance of achieving ‘acceptable’ outcome, because it will deprive other patients of potentially effective treatments.<sup>110</sup> Cost-effectiveness analyses and concepts such as value-based healthcare can be used to substantiate acute treatment decision-making and prevent inefficient use of limited healthcare resources.

**Table 3:** Moral principles in medical ethics

Principle	Description
1. Autonomy	A norm of respecting and supporting autonomous decisions.
2. Beneficence	A group of norms pertaining to relieving, lessening, or preventing harm and providing benefits and balancing benefits against risks and costs.
3. Nonmaleficence	A norm of avoiding the causation of harm.
4. Justice	A group of norms for fairly distributing benefits, risks, and costs.

### In-hospital costs

The true cost-effectiveness and feasibility of the proposed strategy has not been investigated in *this thesis*, and also remains unknown based on the in-hospital healthcare consumption and in-hospital costs that are reported in *chapter 3, 4 and 5*.<sup>6,7,111</sup> It is also difficult to make statements based on available literature, since cost-effectiveness literature in s-TBI is scarce and inconclusive. Some studies report TBI treatment to be cost-effective<sup>112-115</sup>, while others report the opposite.<sup>113,116</sup> The feasibility of the proposed strategy remains unclear and requires further investigation with actual cost-effectiveness analyses.

Cost-effectiveness aside, the average in-hospital costs of s-TBI patients (€26,595)<sup>6</sup> that would be associated with the proposed strategy seem to be acceptable compared to the in-hospital costs for other diseases in the Netherlands. Costs were lower compared to the in-hospital costs of s-TBI for patients with ischaemic stroke (€5,328)<sup>117</sup>, transient ischaemic attack (€2,470)<sup>117</sup>, appendicitis (€3,700), colorectal cancer (€9,777–€19,417)<sup>118</sup>, percutaneous coronary intervention (€14,037) or coronary artery bypass grafting (€17,506)<sup>119</sup>. In-hospital costs were higher for patients with non-small cell lung cancer (€33,143)<sup>120</sup>, ipilimumab treatment in melanoma patients (€73,739)<sup>121</sup> or patients receiving extracorporeal life support treatment (€106,263).<sup>122</sup>

Costs also seem to be acceptable when comparing the in-hospital costs for s-TBI patients with the Dutch cut-off point for cost-effective treatments of €80,000 per Quality-adjusted Life Year (QALY).<sup>123</sup> Although the comparison of reported in-hospital costs with the €80,000 cut-off point for cost-effectiveness analyses is not entirely appropriate, and although there are always few patient outliers with very high costs, the costs of nearly every TBI patient studied in *this thesis* was lower than €80,000.

Both comparisons are illustrative, but have obvious limitations. First, analyses should not only assess in-hospital costs, but all costs associated with s-TBI, including out of hospital and other indirect costs. Only using in-hospital costs results in a major underestimation of the total costs related to s-TBI. Especially when patients survive with severe disabilities, chronic care after hospital discharge, but also loss of productivity, have substantial economic and societal impact.

Including an economic perspective in decision-making is regarded as reasonable because of its objectivity. Focusing on the economic perspective however also fails to recognize individual aspects of care and the social utility of caring for those most in need. People obtain benefit from the belief that they live in a compassionate and humane society where patients in need will not be ignored merely based on costs. Still, there must be a point where TBI is so severe and patient outcome so 'unacceptable' that it does not justify the associated costs. For future decision-making, it would be very helpful to know where that point is.



## FUTURE RESEARCH

The treatment of patients with s-TBI deserves scientific and public attention given the considerable medical and economic burden for patients, proxies, and societies. Treatment decision-making will benefit most from knowing which specific patient will benefit from which specific treatment in terms of cost-effectiveness and patient outcome. Accurate prognostication and the determination of the 'acceptability' of outcome are essential parts of the acute treatment decision-making process. Future studies should focus on investigating:

1. New diagnostic and treatment modalities including their (cost-) effectiveness and their effect on short- and long-term patient outcome.<sup>124,125</sup>
2. The (patho)physiological mechanisms of brain injury and its plasticity.<sup>3,126-130</sup>
3. Reliable, reproducible, validated, free and easy to use outcome assessment tools that are sensitive for disabilities commonly present in s-TBI survivors.<sup>52</sup>
4. Methods to improve the reliability of prognostic or machine learning models.<sup>131,132</sup>
5. The influence of human values, including a dignified existence and the wellbeing of patients, proxies and society.

Different study designs will be required to answer different research questions. Randomized controlled trials (RCTs), the cornerstone of evidence-based medicine, might provide answers to point 1, 3 and 4. Although very little translatable evidence has been derived from 191 completed RCTs for acute TBI management<sup>133</sup>, more sophisticated large multi-centre RCTs in priority areas might still be able to make a valuable contribution.<sup>133</sup>

To allow RCTs in the hyper acute setting of TBI and to increase their quality, efficiency and contribution to the evidence base, optimized research protocols are needed to overcome several complicating factors in the acute and stressful setting, such as; unavailable necessary information (i.e. trauma mechanism, medical history, use of anticoagulants), and a patients' inability to provide informed consent. A rigorous research protocol is essential for any study to be successful and to obtain institutional review board approval. The increased use of informed consent alternatives, such as deferred consent or exception from consent, has the potential to improve efficiency and quality of future emergency interventional studies in patients with an inability to provide informed consent.<sup>134</sup>

Another method to answer research questions related to point 1 and 4 is called “Comparative Effectiveness Research” (CER). With this method, the effectiveness of (surgical and critical care) treatment is investigated by comparing variation between local practices. This method is used in recent TBI research initiatives like CENTER-TBI, TRACK-TBI and Net-QuRe.<sup>119,135,136</sup> CER is a well-known and promising method to assess treatment effectiveness in TBI, but there are also some important limitations.<sup>137</sup> Studies are generally expensive because many centres and participants must be included to reach sufficient statistical power. Also, effect estimates largely depend on the used analytical method. When a RCT or CER design is not possible, the focus should be on patient cohorts, surgical treatments and outcome measures that are as equal as possible. It is highly recommended to use the well-known common data elements.<sup>138</sup> This will improve comparability and generalizability of study results and allow data analyses in large meta-analyses. Point 2 is basically fundamental research and point 3 and 5 require a more humanistic approach to the topic.

## CONCLUSION

Decision-making dilemmas in the acute treatment of s-TBI patients are common. They are caused by insufficient evidence and by uncertainties in outcome prediction and outcome valuation. To decrease uncertainty and improve decision-making, treatment-limiting decisions in a selection of s-TBI patients should be delayed to after at least 72 hours after injury. These patients will receive optimal acute treatment. Although the feasibility and cost-effectiveness of the proposed strategy requires further investigation, it prevents premature treatment-limiting decisions and allows the collection of essential information to improve the identification of patients that will benefit from specific treatment strategies. At the same time, it could prevent ‘unacceptable’ patient outcome and inefficient use of limited healthcare resources in threatened healthcare systems. Including an economic perspective in decision-making is reasonable and essential, but the individual aspects of care and the social utility of caring for those most in need should not be disregarded. Although it is unlikely that all uncertainty will ever be resolved, researchers and ethicists should continue to try to reduce uncertainty in decision-making by improving the scientific quality of evidence.

## REFERENCES:

1. Sanchez GM, BurrIDGE AL. Decision making in head injury management in the Edwin Smith Papyrus. *Neurosurgical focus* 2007; **23**(1): E5.
2. Stein SC, Georgoff P, Meghan S, Mizra K, Sonnad SS. 150 years of treating severe traumatic brain injury: a systematic review of progress in mortality. *J Neurotrauma* 2010; **27**(7): 1343-53.
3. Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. *The Lancet Neurology* 2017; **16**(12): 987-1048.
4. Teasdale G, Jennett B. ASSESSMENT OF COMA AND IMPAIRED CONSCIOUSNESS: A Practical Scale. *The Lancet* 1974; **304**(7872): 81-4.
5. Teasdale G, Maas A, Lecky F, Manley G, Stocchetti N, Murray G. The Glasgow Coma Scale at 40 years: standing the test of time. *The Lancet Neurology* 2014; **13**(8): 844-54.
6. van Dijk J, Mostert CQB, Greeven APA, et al. Functional outcome, in-hospital healthcare consumption and in-hospital costs for hospitalised traumatic brain injury patients: a Dutch prospective multicentre study. *Acta neurochirurgica* 2020; **162**(7): 1607-18.
7. van Dijk J, van Essen TA, Dijkman MD, et al. Functional and patient-reported outcome versus in-hospital costs after traumatic acute subdural hematoma (t-ASDH): a neurosurgical paradox? *Acta neurochirurgica* 2019; **161**(5): 875-84.
8. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen RL. Early management of severe traumatic brain injury. *Lancet (London, England)* 2012; **380**(9847): 1088-98.
9. McIntyre A, Mehta S, Janzen S, Aubut J, Teasell RW. A meta-analysis of functional outcome among older adults with traumatic brain injury. *NeuroRehabilitation* 2013; **32**: 409-14.
10. Grauwmeijer E, Heijenbrok-Kal MH, Peppel LD, et al. Cognition, Health-Related Quality of Life, and Depression Ten Years after Moderate to Severe Traumatic Brain Injury: A Prospective Cohort Study. *J Neurotrauma* 2018; **35**(13): 1543-51.
11. Ruet A, Bayen E, Jourdan C, et al. A Detailed Overview of Long-Term Outcomes in Severe Traumatic Brain Injury Eight Years Post-injury. *Frontiers in neurology* 2019; **10**: 120.
12. Carozzi NE, Kratz AL, Sander AM, et al. Health-related quality of life in caregivers of individuals with traumatic brain injury: development of a conceptual model. *Arch Phys Med Rehabil* 2015; **96**(1): 105-13.
13. Kratz AL, Sander AM, Brickell TA, Lange RT, Carozzi NE. Traumatic brain injury caregivers: A qualitative analysis of spouse and parent perspectives on quality of life. *Neuropsychol Rehabil* 2017; **27**(1): 16-37.
14. Qadeer A, Khalid U, Amin M, Murtaza S, Khaliq MF, Shoaib M. Caregiver's Burden of the Patients With Traumatic Brain Injury. *Cureus* 2017; **9**(8): e1590.
15. Gao G, Wu X, Feng J, et al. Clinical characteristics and outcomes in patients with traumatic brain injury in China: a prospective, multicentre, longitudinal, observational study. *The Lancet Neurology* 2020; **19**(8): 670-7.
16. Steyerberg EW, Wieggers E, Sewalt C, et al. Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study. *The Lancet Neurology* 2019; **18**(10): 923-34.
17. Krishnamoorthy V, Vavilala MS, Mills B, Rowhani-Rahbar A. Demographic and clinical risk factors associated with hospital mortality after isolated severe traumatic brain injury: a cohort study. *J Intensive Care* 2015; **3**: 46.
18. Carney N, Totten AM, O'Reilly C, et al. Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017; **80**(1): 6-15.
19. Synnot A, Bragge P, Lunny C, et al. The currency, completeness and quality of systematic reviews of acute management of moderate to severe traumatic brain injury: A comprehensive evidence map. *PloS one* 2018; **13**(6): e0198676.
20. Bayley MT, Lamontagne ME, Kua A, et al. Unique Features of the INESSS-ONF Rehabilitation Guidelines for Moderate to Severe Traumatic Brain Injury: Responding to Users' Needs. *The Journal of head trauma rehabilitation* 2018; **33**(5): 296-305.
21. Stocchetti N, Poole D, Okonkwo DO. Intracranial pressure thresholds in severe traumatic brain injury: we are not sure : Prudent clinical practice despite dogma or nihilism. *Intensive care medicine* 2018; **44**(8): 1321-3.
22. Kompanje EJ. Prognostication in neurocritical care: just crystal ball gazing? *Neurocrit Care* 2013; **19**(3): 267-8.

23. Hawryluk GWJ, Rubiano AM, Totten AM, et al. Guidelines for the Management of Severe Traumatic Brain Injury: 2020 Update of the Decompressive Craniectomy Recommendations. *Neurosurgery* 2020; **87**(3): 427-34.
24. van Essen TA, de Ruiter GC, Kho KH, Peul WC. Neurosurgical Treatment Variation of Traumatic Brain Injury: Evaluation of Acute Subdural Hematoma Management in Belgium and The Netherlands. *J Neurotrauma* 2017; **34**(4): 881-9.
25. van Veen E, van der Jagt M, Citerio G, et al. End-of-life practices in traumatic brain injury patients: Report of a questionnaire from the CENTER-TBI study. *J Crit Care* 2020; **58**: 78-88.
26. van Essen TA, den Boogert HF, Cnossen MC, et al. Variation in neurosurgical management of traumatic brain injury: a survey in 68 centers participating in the CENTER-TBI study. *Acta neurochirurgica* 2019; **161**(3): 435-49.
27. Volovici V, Ercole A, Citerio G, et al. Variation in Guideline Implementation and Adherence Regarding Severe Traumatic Brain Injury Treatment: A CENTER-TBI Survey Study in Europe. *World neurosurgery* 2019; **125**: e515-e20.
28. Unterhofer C, Hartmann S, Freyschlag CF, Thome C, Ortler M. Severe head injury in very old patients: to treat or not to treat? Results of an online questionnaire for neurosurgeons. *Neurosurgical review* 2018; **41**(1): 183-7.
29. de Kort FAS, Geurts M, de Kort PLM, et al. Advance directives, proxy opinions, and treatment restrictions in patients with severe stroke. *BMC palliative care* 2017; **16**(1): 52.
30. Quinn T, Moskowitz J, Khan MW, et al. What Families Need and Physicians Deliver: Contrasting Communication Preferences Between Surrogate Decision-Makers and Physicians During Outcome Prognostication in Critically Ill TBI Patients. *Neurocrit Care* 2017; **27**(2): 154-62.
31. Turgeon AF, Dorrance K, Archambault P, et al. Factors influencing decisions by critical care physicians to withdraw life-sustaining treatments in critically ill adult patients with severe traumatic brain injury. *CMAJ* 2019; **191**(24): E652-E63.
32. Reuben DB, Tinetti ME. Goal-oriented patient care--an alternative health outcomes paradigm. *The New England journal of medicine* 2012; **366**(9): 777-9.
33. Ho KM. Predicting outcomes after severe traumatic brain injury: science, humanity or both? *Journal of neurosurgical sciences* 2018; **62**(5): 593-8.
34. Letsinger J, Rommel C, Hirschi R, Nirula R, Hawryluk GWJ. The aggressiveness of neurotrauma practitioners and the influence of the IMPACT prognostic calculator. *PLoS one* 2017; **12**(8): e0183552.
35. Williamson T, Ryser MD, Abdelgadir J, et al. Surgical decision making in the setting of severe traumatic brain injury: A survey of neurosurgeons. *PLoS one* 2020; **15**(3): e0228947.
36. Geurts M, de Kort FAS, de Kort PLM, van Tuijl JH, Kappelle LJ, van der Worp HB. Predictive accuracy of physicians' estimates of outcome after severe stroke. *PLoS One* 2017; **12**(9): e0184894.
37. Pratt AK, Chang JJ, Sederstrom NO. A Fate Worse Than Death: Prognostication of Devastating Brain Injury. *Crit Care Med* 2019; **47**(4): 591-8.
38. Collaborators MCT, Perel P, Arango M, et al. Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. *BMJ* 2008; **336**(7641): 425-9.
39. Steyerberg EW, Mushkudiani N, Perel P, et al. Predicting Outcome after Traumatic Brain Injury: Development and International Validation of Prognostic Scores Based on Admission Characteristics. *PLOS Medicine* 2008; **5**(8): e165.
40. Raj R. Prognostic Models in Traumatic Brain Injury. *Dissertation University of Helsinki* 2014.
41. Majdan M, Lingsma HF, Nieboer D, Mauritz W, Rusnak M, Steyerberg EW. Performance of IMPACT, CRASH and Nijmegen models in predicting six month outcome of patients with severe or moderate TBI: an external validation study. *Scand J Trauma Resusc Emerg Med* 2014; **22**: 68.
42. Maeda Y, Ichikawa R, Misawa J, et al. External validation of the TRISS, CRASH, and IMPACT prognostic models in severe traumatic brain injury in Japan. *PLoS one* 2019; **14**(8): e0221791-e.
43. Roozenbeek B, Lingsma HF, Lecky FE, et al. Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. *Critical care medicine* 2012; **40**(5): 1609-17.
44. Han J, King NK, Neilson SJ, Gandhi MP, Ng I. External validation of the CRASH and IMPACT prognostic models in severe traumatic brain injury. *J Neurotrauma* 2014; **31**(13): 1146-52.

45. Moskowitz J, Quinn T, Khan MW, et al. Should We Use the IMPACT-Model for the Outcome Prognostication of TBI Patients? A Qualitative Study Assessing Physicians' Perceptions. *MDM policy & practice* 2018; **3**(1): 2381468318757987.
46. Corrigan JD, Hammond FM. Traumatic brain injury as a chronic health condition. *Arch Phys Med Rehabil* 2013; **94**(6): 1199-201.
47. van Dijk J, Bartels R, Lavrijsen JCM, Ribbers GM, Kompanje EJO, Peul WC. The patient with severe traumatic brain injury: clinical decision-making: the first 60min and beyond. *Current opinion in critical care* 2019; **25**(6): 622-9.
48. Nelson CG, Elta T, Bannister J, Dzandu J, Mangram A, Zach V. Severe Traumatic Brain Injury: A Case Report. *Am J Case Rep* 2016; **17**: 186-91.
49. Boyer F, Audibert G, Baumann C, et al. [Decision-making regarding treatment limitation after severe traumatic brain injury: A survey of French neurosurgeons]. *Neuro-Chirurgie* 2018; **64**(6): 401-9.
50. Honeybul S, Ho KM, Gillett GR. Long-term outcome following decompressive craniectomy: an inconvenient truth? *Current opinion in critical care* 2018; **24**(2): 97-104.
51. Span-Sluyter C, Lavrijsen JCM, van Leeuwen E, Koopmans R. Moral dilemmas and conflicts concerning patients in a vegetative state/unresponsive wakefulness syndrome: shared or non-shared decision making? A qualitative study of the professional perspective in two moral case deliberations. *BMC medical ethics* 2018; **19**(1): 10.
52. Nichol AD, Higgins AM, Gabbe BJ, Murray LJ, Cooper DJ, Cameron PA. Measuring functional and quality of life outcomes following major head injury: common scales and checklists. *Injury* 2011; **42**(3): 281-7.
53. Honeybul S, Gillett GR, Ho KM, Lind CR. Neurotrauma and the rule of rescue. *Journal of medical ethics* 2011; **37**(12): 707-10.
54. McGowan T. Will You Forgive Me for Saving You? *The New England journal of medicine* 2018; **379**(1): 8-9.
55. <https://www.theguardian.com/society/2017/jul/20/when-life-is-a-fate-worse-than-death-assisted-dying> (accessed November 4 2020).
56. Hillman K, Athari F, Forero R. States worse than death. *Current opinion in critical care* 2018; **24**(5): 415-20.
57. Rubin EB, Buehler AE, Halpern SD. States Worse Than Death Among Hospitalized Patients With Serious Illnesses. *JAMA internal medicine* 2016; **176**(10): 1557-9.
58. Graham M. A Fate Worse Than Death? The Well-Being of Patients Diagnosed as Vegetative With Covert Awareness. *Ethical Theory and Moral Practice* 2017; **20**(5): 1005-20.
59. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet (London, England)* 1975; **1**(7905): 480-4.
60. McMillan T, Wilson L, Ponsford J, Levin H, Teasdale G, Bond M. The Glasgow Outcome Scale — 40 years of application and refinement. *Nature Reviews Neurology* 2016; **12**(8): 477-85.
61. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. *J Neurotrauma* 1998; **15**(8): 573-85.
62. Olivecrona M, Honeybul S. A study of the opinions of Swedish healthcare personnel regarding acceptable outcome following decompressive hemicraniectomy for ischaemic stroke. *Acta neurochirurgica* 2018; **160**(1): 95-101.
63. Coons SJ, Rao S, Keininger DL, Hays RD. A comparative review of generic quality-of-life instruments. *Pharmacoeconomics* 2000; **17**(1): 13-35.
64. von Steinbüchel N, Wilson L, Gibbons H, et al. Quality of Life after Brain Injury (QOLIBRI): scale development and metric properties. *J Neurotrauma* 2010; **27**(7): 1167-85.
65. von Steinbüchel N, Wilson L, Gibbons H, et al. Quality of Life after Brain Injury (QOLIBRI): scale validity and correlates of quality of life. *J Neurotrauma* 2010; **27**(7): 1157-65.
66. Wilson L, Marsden-Loftus I, Koskinen S, et al. Interpreting Quality of Life after Brain Injury Scores: Cross-Walk with the Short Form-36. *J Neurotrauma* 2017; **34**(1): 59-65.
67. Findler M, Cantor J, Haddad L, Gordon W, Ashman T. The reliability and validity of the SF-36 health survey questionnaire for use with individuals with traumatic brain injury. *Brain Inj* 2001; **15**(8): 715-23.
68. Chiu WT, Huang SJ, Hwang HF, et al. Use of the WHOQOL-BREF for evaluating persons with traumatic brain injury. *J Neurotrauma* 2006; **23**(11): 1609-20.
69. Turnbull AE, Chessare CM, Coffin RK, Needham DM. More than one in three proxies do not know their loved one's current code status: An observational study in a Maryland ICU. *PLoS one* 2019; **14**(1): e0211531.

70. Fried TR, Zenoni M, Iannone L, O'Leary JR. Assessment of Surrogates' Knowledge of Patients' Treatment Goals and Confidence in Their Ability to Make Surrogate Treatment Decisions. *JAMA internal medicine* 2019; **179**(2): 267-8.
71. Waqas M, Malik N, Shamim MS, Nathani KR, Abbasi SA. Quality of Life Among Patients Undergoing Decompressive Craniectomy for Traumatic Brain Injury Using Glasgow Outcome Scale Extended and Quality of Life After Brain Injury Scale. *World neurosurgery* 2018; **116**: e783-e90.
72. Honeybul S. Long-term outcome following severe traumatic brain injury: ethical considerations. *Journal of neurosurgical sciences* 2018; **62**(5): 599-605.
73. Ubel PA, Loewenstein G, Schwarz N, Smith D. Misimagining the unimaginable: the disability paradox and health care decision making. *Health Psychol* 2005; **24**(4S): S57-62.
74. Rousseau M-C, Baumstarck K, Alessandrini M, Blandin V, Billette de Villemeur T, Auquier P. Quality of life in patients with locked-in syndrome: Evolution over a 6-year period. *Orphanet J Rare Dis* 2015; **10**: 88-.
75. Andrews JC, Wahl RA. Duchenne and Becker muscular dystrophy in adolescents: current perspectives. *Adolesc Health Med Ther* 2018; **9**: 53-63.
76. Honeybul S, Gillett GR, Ho KM, Janzen C, Kruger K. Is life worth living? Decompressive craniectomy and the disability paradox. 2016; **125**(3): 775.
77. Christakis N. Death foretold: Prophecy and prognosis in medical care. Chicago: Chicago press; 1999.
78. Leblanc G, Boutin A, Shemilt M, et al. Incidence and impact of withdrawal of life-sustaining therapies in clinical trials of severe traumatic brain injury: A systematic review. *Clinical trials (London, England)* 2018; **15**(4): 398-412.
79. Izzy S, Compton R, Carandang R, Hall W, Muehlschlegel S. Self-fulfilling prophecies through withdrawal of care: do they exist in traumatic brain injury, too? *Neurocritical care* 2013; **19**(3): 347-63.
80. Vedantam A, Robertson CS, Gopinath SP. Clinical characteristics and temporal profile of recovery in patients with favorable outcomes at 6 months after severe traumatic brain injury. *Journal of neurosurgery* 2018; **129**(1): 234-40.
81. Rubin ML, Yamal JM, Chan W, Robertson CS. Prognosis of 6-month Glasgow Outcome Scale in severe traumatic brain injury using hospital admission characteristics, injury severity characteristics, and physiological monitoring during the first day post-injury. *J Neurotrauma* 2019.
82. Harvey D, Butler J, Groves J, et al. Management of perceived devastating brain injury after hospital admission: a consensus statement from stakeholder professional organizations. *Br J Anaesth* 2018; **120**(1): 138-45.
83. Smith LGF, Milliron E, Ho M-L, et al. Advanced neuroimaging in traumatic brain injury: an overview. 2019; **47**(6): E17.
84. Jain S, Vyvere TV, Terzopoulos V, et al. Automatic Quantification of Computed Tomography Features in Acute Traumatic Brain Injury. *J Neurotrauma* 2019; **36**(11): 1794-803.
85. Yuh EL, Cooper SR, Ferguson AR, Manley CT. Quantitative CT improves outcome prediction in acute traumatic brain injury. *J Neurotrauma* 2012; **29**(5): 735-46.
86. Vande Vyvere T, De La Rosa E, Wilms G, et al. Prognostic Validation of the NINDS Common Data Elements for the Radiologic Reporting of Acute Traumatic Brain Injuries: A CENTER-TBI Study. *J Neurotrauma* 2020; **37**(11): 1269-82.
87. Grignoli N, Di Bernardo V, Malacrida R. New perspectives on substituted relational autonomy for shared decision-making in critical care. *Crit Care* 2018; **22**(1): 260.
88. Khan MW, Muehlschlegel S. Shared Decision Making in Neurocritical Care. *Neurosurgery clinics of North America* 2018; **29**(2): 315-21.
89. Robertsen A, Førde R, Skaga NO, Helseth E. Treatment-limiting decisions in patients with severe traumatic brain injury in a Norwegian regional trauma center. *Scandinavian journal of trauma, resuscitation and emergency medicine* 2017; **25**(1): 44.
90. Williamson T, Ryser MD, Ubel PA, et al. Withdrawal of Life-Supporting Treatment in Severe Traumatic Brain Injury. *JAMA Surg* 2020; **155**(8): 723-31.
91. Souter MJ, Blissitt PA, Blosser S, et al. Recommendations for the Critical Care Management of Devastating Brain Injury: Prognostication, Psychosocial, and Ethical Management : A Position Statement for Healthcare Professionals from the Neurocritical Care Society. *Neurocritical care* 2015; **23**(1): 4-13.
92. Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. *Neuropharmacology* 2019; **145**(Pt B): 230-46.

93. Xue M, Yong VW. Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation. *The Lancet Neurology* 2020; **19**(12): 1023-32.
94. Cronberg T, Greer DM, Lilja G, Moolaert V, Swindell P, Rossetti AO. Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation. *The Lancet Neurology* 2020; **19**(7): 611-22.
95. Turgeon AF, Lauzier F, Simard JF, et al. Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort study. *CMAJ* 2011; **183**(14): 1581-8.
96. Giacino JT, Katz DI, Schiff ND, et al. Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. *Neurology* 2018; **91**(10): 450-60.
97. Avesani R, Dambruoso F, Scandola M, et al. Epidemiological and clinical characteristics of 492 patients in a vegetative state in 29 Italian rehabilitation units. What about outcome? *Functional neurology* 2018; **33**(2): 97-103.
98. J.J. Fins. *Rights come to mind*: Cambridge University Press; 2015.
99. van Veen E, van der Jagt M, Cnossen MC, et al. Brain death and postmortem organ donation: report of a questionnaire from the CENTER-TBI study. *Crit Care* 2018; **22**(1): 306.
100. Lesieur O, Genteuil L, Leloup M. A few realistic questions raised by organ retrieval in the intensive care unit. *Ann Transl Med* 2017; **5**(Suppl 4): S44.
101. Rohaut B, Eliseyev A, Claassen J. Uncovering Consciousness in Unresponsive ICU Patients: Technical, Medical and Ethical Considerations. *Crit Care* 2019; **23**(1): 78.
102. Bruno MA, Majerus S, Boly M, et al. Functional neuroanatomy underlying the clinical subcategorization of minimally conscious state patients. *J Neurol* 2012; **259**(6): 1087-98.
103. Papanicolaou I, Woskie LR, Jha AK. Health Care Spending in the United States and Other High-Income Countries. *JAMA* 2018; **319**(10): 1024-39.
104. Stocchetti N, Carbonara M, Citerio G, et al. Severe traumatic brain injury: targeted management in the intensive care unit. *The Lancet Neurology* 2017; **16**(6): 452-64.
105. Czech H, Druml C, Weindling P. Medical Ethics in the 70 Years after the Nuremberg Code, 1947 to the Present. *Wiener klinische Wochenschrift* 2018; **130**(3): 159-253.
106. Parsa-Parsi RW. The Revised Declaration of Geneva: A Modern-Day Physician's Pledge. *JAMA* 2017; **318**(20): 1971-2.
107. Beauchamp TC J. *Principles of biomedical ethics*. 7th ed. New York: Oxford University Press; 2013.
108. Porter ME, Lee TH. The Strategy That Will Fix Health Care. *Harvard Business Review* 2013; **October 2013 Issue**
109. MacKillop E, Sheard S. Quantifying life: Understanding the history of Quality-Adjusted Life-Years (QALYs). *Soc Sci Med* 2018; **211**: 359-66.
110. Kompanje EJ, Piers RD, Benoit DD. Causes and consequences of disproportionate care in intensive care medicine. *Curr Opin Crit Care* 2013; **19**(6): 630-5.
111. van Dijk J, Dijkman MD, Ophuis RH, de Ruiter GCW, Peul WC, Polinder S. In-hospital costs after severe traumatic brain injury: A systematic review and quality assessment. *PLoS one* 2019; **14**(5): e0216743.
112. Whitmore RG, Thawani JP, Grady MS, Levine JM, Sanborn MR, Stein SC. Is aggressive treatment of traumatic brain injury cost-effective? *Journal of neurosurgery* 2012; **116**(5): 1106-13.
113. Ho KM, Honeybul S, Lind CR, Gillett GR, Litton E. Cost-effectiveness of decompressive craniectomy as a lifesaving rescue procedure for patients with severe traumatic brain injury. *J Trauma* 2011; **71**(6): 1637-44; discussion 44.
114. Malmivaara K, Kivisaari R, Hernesniemi J, Siironen J. Cost-effectiveness of decompressive craniectomy in traumatic brain injuries. *European Journal of Neurology* 2011; **18**(4): 656-62.
115. Alali A, Burton K, Fowler R, et al. Economic evaluations in the diagnosis and management of traumatic brain injury: a systematic review and analysis of quality. *Value Health* 2015; **18**(5): 721-34.
116. Knott R.J. HA, Higgins A., Nichol A., French C., Little L., Haddad S., Presnell J. Cost-Effectiveness of Erythropoietin in Traumatic Brain Injury: A Multinational Trial-Based Economic Analysis. *Journal of Neurotrauma* 2019; **36**(17): 2541-8.
117. Buisman LR, Tan SS, Nederkoorn PJ, Koudstaal PJ, Redekop WK. Hospital costs of ischemic stroke and TIA in the Netherlands. *Neurology* 2015; **84**(22): 2208-15.

118. Govaert JA, van Dijk WA, Fiocco M, et al. Nationwide Outcomes Measurement in Colorectal Cancer Surgery: Improving Quality and Reducing Costs. *J Am Coll Surg* 2016; **222**(1): 19-29.e2.
119. Maas AI, Menon DK, Steyerberg EW, et al. Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): a prospective longitudinal observational study. *Neurosurgery* 2015; **76**(1): 67-80.
120. van der Linden N, Bongers ML, Coupe VM, et al. Costs of non-small cell lung cancer in the Netherlands. *Lung Cancer* 2016; **91**: 79-88.
121. Franken MG, Leeneman B, Jochems A, et al. Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. *Anti-cancer drugs* 2018; **29**(6): 579-88.
122. Oude Lansink-Hartgring A, van den Hengel B, van der Bij W, et al. Hospital Costs Of Extracorporeal Life Support Therapy. *Critical care medicine* 2016; **44**(4): 717-23.
123. Nederland Zorgautoriteit. Ziektelast in de praktijk - de theorie en de praktijk van het berekenen van ziektelast bij pakketbeoordelingen. 2018. [https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2018/05/07/ziektelast-in-de-praktijk/Ziektelast+in+de+praktijk\\_definitief.pdf](https://www.zorginstituutnederland.nl/binaries/zinl/documenten/rapport/2018/05/07/ziektelast-in-de-praktijk/Ziektelast+in+de+praktijk_definitief.pdf).
124. Kochanek PM, Jackson TC, Jha RM, et al. Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision. *Journal of neurotrauma* 2019.
125. Wang KK, Yang Z, Zhu T, et al. An update on diagnostic and prognostic biomarkers for traumatic brain injury. *Expert review of molecular diagnostics* 2018; **18**(2): 165-80.
126. Vrselja Z, Daniele SG, Silbereis J, et al. Restoration of brain circulation and cellular functions hours post-mortem. *Nature* 2019; **568**(7752): 336-43.
127. O'Leary RA, Nichol AD. Pathophysiology of severe traumatic brain injury. *Journal of neurosurgical sciences* 2018; **62**(5): 542-8.
128. Hylin MJ, Kerr AL, Holden R. Understanding the Mechanisms of Recovery and/or Compensation following Injury. *Neural Plast* 2017; **2017**: 7125057.
129. Piradov MA, Chernikova LA, Suponeva NA. Brain Plasticity and Modern Neurorehabilitation Technologies. *Herald of the Russian Academy of Sciences* 2018; **88**(2): 111-8.
130. Kaur P, Sharma S. Recent Advances in Pathophysiology of Traumatic Brain Injury. *Current neuropharmacology* 2018; **16**(8): 1224-38.
131. Rau CS, Kuo PJ, Chien PC, Huang CY, Hsieh HY, Hsieh CH. Mortality prediction in patients with isolated moderate and severe traumatic brain injury using machine learning models. *PLoS One* 2018; **13**(11): e0207192.
132. Hale AT, Stonko DP, Brown A, et al. Machine-learning analysis outperforms conventional statistical models and CT classification systems in predicting 6-month outcomes in pediatric patients sustaining traumatic brain injury. *Neurosurgical focus* 2018; **45**(5): E2.
133. Bragge P, Synnot A, Maas AI, et al. A State-of-the-Science Overview of Randomized Controlled Trials Evaluating Acute Management of Moderate-to-Severe Traumatic Brain Injury. *J Neurotrauma* 2016; **33**(16): 1461-78.
134. Kompanje EJO, van Dijck J, Chalos V, et al. Informed consent procedures for emergency interventional research in patients with traumatic brain injury and ischaemic stroke. *The Lancet Neurology* 2020; **19**(12): 1033-42.
135. Van Essen TA, Volovici V, Cnossen MC, et al. Comparative effectiveness of surgery in traumatic acute subdural and intracerebral haematoma: study protocol for a prospective observational study within CENTER-TBI and Net-QuRe. *BMJ Open* 2019; **9**(10): e033513.
136. Investigators T-T. Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI). ClinicalTrials.gov Identifier: NCT02119182. 2014. <https://clinicaltrials.gov/ct2/show/study/NCT02119182>.
137. Cnossen M. Outcome and comparative effectiveness research in traumatic brain injury : a methodological perspective [Ph.D. thesis]: Erasmus University Rotterdam; 2017.
138. Meeuws S, Yue JK, Huijben JA, et al. Common Data Elements: Critical Assessment of Harmonization between Current Multi-Center Traumatic Brain Injury Studies. *J Neurotrauma* 2020; **37**(11): 1283-90.